InsidersTradesSigma
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
无可用的信号评分。
Explore the full record of transactions filed by Snyder Mark Howard. Officer active across 1 company, notably Halozyme Therapeutics, INC.. Cumulatively, 10 filings have been recorded. History available since 3 January 2023. The latest transaction was disclosed on 20 February 2026 (Levée d'options). Regulator: SEC (Form 4). All data is free.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
10 条申报中的 10 条
Snyder Mark Howard is SVP, CHIEF LEGAL OFFICER at Halozyme Therapeutics, INC. He has 10 filings in total, and among the 10 sampled filings the period runs from 2023-01-04 to 2026-02-24. The most frequent transaction nature is Option exercise, and the buy and sell amounts are EUR 0 and EUR 0.